International journal of clinical oncology · 2026
Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hirakawa Tetsu, Yamaguchi Kakuhiro, Shimoji Kiyofumi, Sakamoto Shinjiro, Horimasu Yasushi, Masuda Takeshi, Nakashima Taku, Iwamoto Hiroshi, Hamada Hironobu, Hattori Noboru
Аннотация
BACKGROUND: Vascular endothelial growth factor (VEGF)-A, which is overexpressed in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), has been implicated in resistance to EGFR-tyrosine kinase inhibitors (TKIs). VEGF-A comprises several isoforms, including VEGF121 and VEGF165. However, the clinical potential as blood biomarkers in EGFR-TKI treatment remains unclear.
METHODS: We retrospectively analyzed 64 patients with advanced EGFR-mutated NSCLC who received EGFR-TKI monotherapy at Hiroshima University Hospital between November 2009 and August 2023. Pre-treatment serum levels of total VEGF-A (tVEGF-A), VEGF121, and VEGF165 were measured using enzyme-linked immunosorbent assays. The association of these biomarkers with the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was analyzed.
RESULTS: The ORR was 78.1%, and the median PFS and OS were 7.5 and 31.8 months, respectively. Serum VEGF121 levels were significantly higher in non-responders than in responders (median, 446.6 vs. 322.1 pg/mL, p = 0.043), whereas no significant differences were observed for tVEGF-A and VEGF165 levels. Receiver operating characteristic analysis identified an optimal serum VEGF121 cut-off level of 339.3 pg/mL (AUC: 0.678, sensitivity: 52.0%, specificity: 92.9%). Patients with higher serum VEGF121 (> 339.3 pg/mL) had significantly lower ORR (64.9% vs. 96.3%, p = 0.003), shorter PFS (median, 6.2 vs. 14.4 months, p = 0.026), and shorter OS (median, 27.6 months vs. not reached, p = 0.040) than those with lower serum VEGF121 (≤ 339.3 pg/mL).
CONCLUSION: Higher levels of serum VEGF121 were associated with lower EGFR-TKI efficacy and poorer prognosis in patients with EGFR-mutated NSCLC.
METHODS: We retrospectively analyzed 64 patients with advanced EGFR-mutated NSCLC who received EGFR-TKI monotherapy at Hiroshima University Hospital between November 2009 and August 2023. Pre-treatment serum levels of total VEGF-A (tVEGF-A), VEGF121, and VEGF165 were measured using enzyme-linked immunosorbent assays. The association of these biomarkers with the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was analyzed.
RESULTS: The ORR was 78.1%, and the median PFS and OS were 7.5 and 31.8 months, respectively. Serum VEGF121 levels were significantly higher in non-responders than in responders (median, 446.6 vs. 322.1 pg/mL, p = 0.043), whereas no significant differences were observed for tVEGF-A and VEGF165 levels. Receiver operating characteristic analysis identified an optimal serum VEGF121 cut-off level of 339.3 pg/mL (AUC: 0.678, sensitivity: 52.0%, specificity: 92.9%). Patients with higher serum VEGF121 (> 339.3 pg/mL) had significantly lower ORR (64.9% vs. 96.3%, p = 0.003), shorter PFS (median, 6.2 vs. 14.4 months, p = 0.026), and shorter OS (median, 27.6 months vs. not reached, p = 0.040) than those with lower serum VEGF121 (≤ 339.3 pg/mL).
CONCLUSION: Higher levels of serum VEGF121 were associated with lower EGFR-TKI efficacy and poorer prognosis in patients with EGFR-mutated NSCLC.